Reports by Industry
Reports by Company
- Company Analysis(173)
- Company Profile(60)
New Diabetes Drug by University of Utah
Mar 28, 2007
The study by University of Utah was conducted on mice and rats that develop diseases similar to diabetes. The study showed that obstructing the formation of a fat molecule, called ceramide, helped check insulin resistance. Ceramide is connected to saturated fats, stated Scott Summers, Ph.D., Associate Professor of internal medicine and one of the authors of the study, in a statement reported on March 7, 2007 by The Salt Lake Tribune.
The findings may give new ways of treating or even preventing the type 2 diabetes. Also, to an extent, it has the potential to treat type 1 diabetes also, something researchers have a grant to look into, said Summers.
He added, “If we pre-treated with this drug, [the animals] never became diabetic”. This kind of treatment would be for people suffering from type 2 diabetes, the most common diabetes form, said Summers.
According William Holland, the lead author of the study, on March 7, 2007, said in a statement reported by The Salt Lake Tribune, that some existing drug treatments make the body more susceptible to the quantum of the insulin produced naturally in the body. But the findings of the University of Utah proffer another way to treat the insulin resistance.
According William Holland, the lead author of the study, on March 7, 2007, said in a statement reported by The Salt Lake Tribune, that some existing drug treatments make the body more susceptible to the quantum of the insulin produced naturally in the body. But the findings of the University of Utah proffer another way to treat the insulin resistance.
“We show that preventing ceramide accumulation in a number of different [mouse and rat] models . . . will improve insulin sensitivity”, added Holland.
The drugs tested on animal models may cause severe side effects in human beings. So pharmaceutical firms will have to look for new methods to target ceramide molecule in patients. It could take a long time of 10 years before a suitable human drug passes through the stage of clinical trials.
The RNCOS report “Insulin Delivery Systems Market Analysis (2007-2010)” projects the diabetes drugs and equipment market to go beyond US$ 20 Billion by 2010. This segment continues to see radical development in research for both technologies and therapeutic compounds in drug delivery.
The market research report provides an insight into the global diabetes drug market. It highlights the worldwide trends in insulin supply and demand, insulin delivery market, various diabetes treatments (including gene therapy, pump therapy, and Xenotransplantation), key drivers, and future outlook of the market.
For more information visit: http://www.rncos.com/Report/IM509.htm
The market research report provides an insight into the global diabetes drug market. It highlights the worldwide trends in insulin supply and demand, insulin delivery market, various diabetes treatments (including gene therapy, pump therapy, and Xenotransplantation), key drivers, and future outlook of the market.
For more information visit: http://www.rncos.com/Report/IM509.htm
Some of our Related Reports are as follows:Â
Related Releases are as follows:
- Green Go to Derma Clinical Trial - How will it Shape Industry?
- Liquid Biopsy Paving the Way to Growth through Strategic Transactions
- India- A Largely Untapped Market for NIPT
- Government Initiatives Promoting the Indian Healthcare Sector
- Clinical Chemistry Testing Major Driver for US Clinical Laboratory Testing Market
Media Citation
- testtest
19 Jan, 2024 - Yourstory.com News @ Foodtech startup Swiggy launches Health Hub in Chennai
23 Mar, 2021 - Yourstory.com News @ Zomato forays into dietary supplements, makes its own 'made in India' brand
16 Mar, 2021 - View more
get in touch
Copyright © 2014, RNCOS, 2002-2014
About Us
Terms & Policy
Contact